Capital International Investors Acquires 233,466 Shares of Xenon Pharmaceuticals Inc. $XENE

Capital International Investors grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,414,959 shares of the biopharmaceutical company’s stock after acquiring an additional 233,466 shares during the quarter. Capital International Investors owned about 4.42% of Xenon Pharmaceuticals worth $153,058,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Blue Trust Inc. lifted its position in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the last quarter. Danske Bank A S bought a new stake in Xenon Pharmaceuticals in the 3rd quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in Xenon Pharmaceuticals in the 3rd quarter worth approximately $39,000. State of Wyoming lifted its position in Xenon Pharmaceuticals by 112.8% in the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 610 shares during the last quarter. Finally, Clearstead Advisors LLC lifted its position in Xenon Pharmaceuticals by 214.8% in the 4th quarter. Clearstead Advisors LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 829 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $51.21 on Tuesday. The business’s 50 day simple moving average is $55.74 and its two-hundred day simple moving average is $48.68. The stock has a market capitalization of $4.95 billion, a P/E ratio of -10.90 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a one year low of $30.00 and a one year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the firm earned ($0.83) earnings per share. Sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

XENE has been the subject of a number of recent research reports. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Deutsche Bank Aktiengesellschaft boosted their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Needham & Company LLC dropped their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $77.20.

Insiders Place Their Bets

In related news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christopher John Kenney sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the transaction, the insider owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. This represents a 16.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 12,572 shares of company stock worth $689,101. 4.07% of the stock is currently owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.